Saudi marketUpdated November 4

SFDA discusses biotech cooperation with Korean firms

Okaz reported that Saudi Food and Drug Authority (SFDA) CEO Dr. Hisham Aljadhey met Korean private-sector representatives at a roundtable in Seoul, South Korea, on the sidelines of the annual ICMRA summit. They discussed potential cooperation, scientific and regulatory exchange, research and technical capabilities, and requirements and pathways for registering modern treatments. Aljadhey outlined SFDA pathways intended to keep pace with scientific and technical developments and facilitate treatment registration and access, subject to quality, effectiveness and safety requirements. These include a pathway for rare-disease medicines and newly introduced pathways for advanced therapies. The discussion sits within the national biotechnology strategy’s ambition for Saudi Arabia to become a leading global biotechnology hub, aligned with Vision 2030. Okaz also describes a Riyadh biotechnology institution’s role in supporting research, innovation and partnerships.

1 publisher1 report

Coverage started November 4